Visão geral da empresa
A biopharmaceutical enterprise, BridgeBio Pharma, Inc., is dedicated to the discovery, development, and delivery of therapeutic medicines specifically targeting patients suffering from genetic diseases. The company operates within the Healthcare sector and functions as a Biotechnology industry player, an environment characterized by high R&D expenditures and regulatory scrutiny for novel drug candidates. The organization employs a workforce of 834 individuals and holds a total market capitalization of $14.37B, while reporting annual revenue (TTM) of $502.08M. These valuation and revenue figures suggest a significant market presence that is disproportionately large relative to its current profitability, indicating that the market price reflects substantial expectations regarding the future commercial success of its pipeline assets, particularly its near-complete TTR stabilizer.
Saúde financeira
BridgeBio Pharma, Inc. reported a revenue of $502.08M for the trailing twelve months, yet simultaneously recorded a net income of $-724,931,008 and an EBITDA of $-496,630,016. The substantial gap between the positive revenue figure and the deeply negative net income reveals a cost structure where operating expenses and research costs far exceed current sales proceeds, a common dynamic in early-to-mid stage biotechnology firms. The company generated a free cash flow of $-325,290,624, which indicates a negative financial flexibility requiring continuous capital infusion to maintain operations and fund clinical trials. Despite these outflows, the balance sheet holds $587.48M in cash against a total debt load of $1.86B, resulting in a debt-to-equity ratio that is not applicable due to the specific accounting presentation of equity in this sector. The current ratio stands at 2.77, signaling that the company possesses sufficient liquid assets to cover its short-term liabilities with a comfortable margin of safety. Return on Equity is not applicable, while the Return on Assets is -33.8%, revealing that the company is currently destroying value on its asset base as it burns through capital to develop its product portfolio.
Avaliação de valorização
The trailing twelve-month P/E ratio is not applicable, whereas the forward P/E is listed at 37070.00, a stark disparity that implies the market is pricing in significant future earnings growth that has not yet been realized in historical financial statements. The price-to-book ratio is -6.92, indicating that the market capitalization is priced significantly below the company's book value, a metric often seen in loss-making biotechnology firms where intangible assets and pipeline potential are not fully captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 28.63 and an EV/EBITDA of -31.53 suggest that investors are willing to pay a premium for revenue generation without immediate regard for current profitability or earnings per share. Regarding trading ranges, the stock has a 52-week high of $84.94 and a 52-week low of $28.32; the current market price sits within this historical volatility range, reflecting the uncertainty surrounding the company's upcoming milestones. The beta value is 1.09, which indicates that the stock's price volatility is slightly higher than the broader market, suggesting it may amplify market movements during periods of sector-specific turbulence or general equity market shifts.
Growth & Income
The company experienced a revenue growth year-over-year of 2521.2%, while earnings growth year-over-year is not applicable due to the persistent net losses. The absence of earnings growth metrics relative to the explosive revenue growth implies that the company is prioritizing top-line expansion and market penetration over immediate profitability, a strategy typical for firms in the biotechnology sector focused on launching new therapies. As a non-dividend payer, BridgeBio Pharma, Inc. reports a dividend yield of not applicable and a payout ratio of 0.0%, meaning the company reinvests all available capital back into research and development rather than distributing income to shareholders. This profile characterizes BridgeBio Pharma, Inc. as a pure growth-oriented asset that offers no current income stream but relies entirely on the successful commercialization of its genetic disease treatments to eventually generate shareholder returns.